Sesen Bio Inc (NASDAQ:SESN)

0.3866
Delayed Data
As of Sep 29
 -0.0017 / -0.43%
Today’s Change
0.37
Today|||52-Week Range
1.47
-52.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$81.6M

Company Description

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Contact Information

Sesen Bio, Inc.
245 First Street
Cambridge Massachusetts 02142
P:(617) 444-8550
Investor Relations:

Employees

Shareholders

Mutual fund holders8.36%
Other institutional5.90%
Individual stakeholders1.52%

Top Executives

Thomas R. CannellPresident, Chief Executive Officer & Director
Monica ForbesChief Financial Officer & Treasurer
Stephanie VigueFinance Director
Jeannick CizeauHead of Research
Glen C. MacDonaldChief Technology Officer